ArticleJournal of thoracic disease2026
Elevated serum Cyfra 21-1 levels predict poor prognosis in thymic tumors: a retrospective single-center study.
Article in Journal of thoracic disease, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Currently, specific serum biomarkers for thymic tumors remain poorly characterized. This study aimed to investigate the diagnostic and prognostic value of potentially relevant serum tumor markers in this context. Methods: Consecutive patients with thymic tumors treated at Shanghai Chest Hospital between November 2012 and December 2017 were retrospectively enrolled in this study. Serum levels of tumor markers, including carcinoembryonic antigen (CEA), cytokeratin 19 fragment (Cyfra 21-1), squamous cell carcinoma antigen (SCCA), neuron-specific enolase (NSE), and carbohydrate antigen 125 (CA125), were evaluated across clinical and pathological subgroups. Survival analyses were performed using Kaplan-Meier curves and Cox regression models. Results: A total of 301 consecutive patients were enrolled in the study, of whom 231 had thymomas, 58 had thymic carcinomas (TCs), and 12 had neuroendocrine tumors (NETs). None of the markers-CEA, SCCA, NSE, or CA125-showed significant associations with tumor characteristics or prognosis. Conversely, elevated Cyfra 21-1 levels were significantly associated with advanced tumor (T) stage [odds ratio (OR): 3.259, 95% confidence interval (CI): 1.250-8.496, P=0.02] and high-grade malignancies, including TCs and NETs (OR: 6.260, 95% CI: 2.491-15.736, P<0.001). After a median follow-up of 60 months, among the 222 patients who underwent upfront complete (R0) resection, elevated preoperative Cyfra 21-1 levels independently predicted worse freedom from recurrence [FFR; hazard ratio (HR): 7.590, 95% CI: 2.316-24.87, P=0.001). Conclusions: Cyfra 21-1 demonstrates potential as a valuable serum biomarker for both the diagnosis and prognosis of thymic tumors. Particular attention should be directed toward the diagnosis, treatment strategy, and postoperative surveillance of patients presenting with elevated Cyfra 21-1 levels.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.